| Literature DB >> 30072577 |
Kyle W Knouse1, Justine N deGruyter1, Michael A Schmidt2, Bin Zheng3, Julien C Vantourout1, Cian Kingston1, Stephen E Mercer4, Ivar M Mcdonald4, Richard E Olson4, Ye Zhu3, Chao Hang3, Jason Zhu3, Changxia Yuan3, Qinggang Wang3, Peter Park5, Martin D Eastgate2, Phil S Baran6.
Abstract
<span class="Chemical">Phosphorothioate nucleotides have emerged as powerful pharmacological substitutes of their native phosphodiester analogs with important translational applications in antisense <span class="Chemical">oligonucleotide (ASO) therapeutics and cyclic dinucleotide (CDN) synthesis. Stereocontrolled installation of this chiral motif has long been hampered by the systemic use of phosphorus(III) [P(III)]-based reagent systems as the sole practical means of oligonucleotide assembly. A fundamentally different approach is described herein: the invention of a P(V)-based reagent platform for programmable, traceless, diastereoselective phosphorus-sulfur incorporation. The power of this reagent system is demonstrated through the robust and stereocontrolled synthesis of various nucleotidic architectures, including ASOs and CDNs, via an efficient, inexpensive, and operationally simple protocol.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30072577 PMCID: PMC6349427 DOI: 10.1126/science.aau3369
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728